MedTrace Logo

A Study to Investigate the Safety of AB680 in Healthy Volunteers

NCT03677973 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2024-05-24

No results posted yet for this study

Summary

This is a double-blind, randomized, placebo-controlled, single- and multiple-ascending dose study to investigate the safety, tolerability, and pharmacokinetic profile of AB680 in healthy volunteers.

Conditions

  • Healthy Volunteers

Interventions

DRUG

AB680

AB680 is a Cluster of Differentiation (CD)73 Inhibitor

OTHER

Placebo

Matching Placebo

Sponsors & Collaborators

  • Arcus Biosciences, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-10-16
Primary Completion
2019-08-19
Completion
2019-08-19

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03677973 on ClinicalTrials.gov